LP
LPCN icon

LMR Partners’s Lipocine LPCN Stock Holding History

LMR Partners’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,530
Closed -$173K – 455
2017
Q2 		$173K Buy
+2,530
New +$165K 0.01% 538

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LMR Partners's LPCN Position: Q3 2017 in Review

LMR Partners sold out of Lipocine (LPCN) in Q3 2017, closing a stake of 2,530 shares — an estimated $173K sold.

LMR Partners first reported a position in LPCN in Q2 2017 and held it in 1 quarter. The position peaked at $173K in Q2 2017. 37 funds tracked by Wall St. Rank hold LPCN as of Q3 2017.

  • LMR Partners reported no remaining Lipocine position as of Q3 2017 after selling out during the quarter.
  • LMR Partners sold 2,530 Lipocine shares in Q3 2017, an estimated $173K.
  • LMR Partners first reported a position in Lipocine in Q2 2017 and held it in 1 quarter.
  • LMR Partners's Lipocine position peaked at $173K in Q2 2017.
  • 37 funds tracked by Wall St. Rank held Lipocine as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.